Expertos Invitados





PAPEL DEL MONTELUKAST EN LA RINITIS ALERGICA

(especial para SIIC © Derechos reservados)
El tratamiento con montelukast es eficaz y seguro en la rinitis alérgica; la información sugiere que el montelukast es superior al placebo. Su efecto es similar al de los antihistamínicos, pero es menos eficaz en comparación con los corticoides intranasales. La respuesta clínica es variable, posiblemente en relación con las variaciones genéticas en la vía de la 5-lipooxigenasa.
Autor:
Ibrahim Sayin
Columnista Experto de SIIC

Institución:
Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Artículos publicados por Ibrahim Sayin
Coautores
Cemal Cingi* Duygu Demirbas** 
Eskisehir Osmangazi University, Eskisehir, Turquía*
Memorial Hospital, Estanbul, Turquía**

PAPEL DEL MONTELUKAST EN LA RINITIS ALERGICA

Resumen
La rinitis alérgica es un problema de salud mundial que afecta significativamente la calidad de vida de los enfermos. El tratamiento eficaz es necesario para evitar las consecuencias sociales y económicas y las comorbilidades. Los antagonistas de los receptores de los leucotrienos (ARLT) se crearon originalmente para el tratamiento del asma. Las propiedades fisiopatológicas similares y la elevada coincidencia de asma y rinitis alérgica motivaron el uso de los ARLT en la rinitis alérgica. En este trabajo se presenta una revisión del montelukast, un ARLT, en relación con los mecanismos de acción, la eficacia clínica, los efectos en los estudios de comparación con otras terapias disponibles, como corticoides intranasales y antihistamínicos, y placebo, los efectos adversos y la mutagenicidad y teratogenicidad.

Palabras clave
montelukast, antagonistas de los receptores de los leucotrienos, placebo, antihistamínicos, aerosol nasal, efectos adversos


Artículo completo
(castellano)
Extensión:  +/-8.05 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Role of montelukast in allergic rhinitis

Abstract
Allergic rhinitis (AR) is a global health problem that significantly affects quality of life. Effective treatment is needed to minimize its associated comorbidity as well as social and economic consequences. Leukotriene receptor antagonists (LTRAs) were first developed to treat asthma. Due to the similar pathophysiological properties of asthma and allergic rhinitis and their high coincidence, LTRAs may be helpful to treat AR. This report provides a review of one LTRA, montelukast, with regard to its acting mechanism, clinical efficiency, and comparative studies with existing therapies including intranasal corticosteroid therapy, antihistamine or placebo, side effects, and mutagenicity/teratogenity.

Key words
montelukast, leukotriene receptor antagonist, placebo, antihistamine, topical nasal spray, side effect


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Alergia, Inmunología
Relacionadas: Atención Primaria, Bioquímica, Farmacología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 8.05 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Cemal Cingi, Eskisehir Osmangazi University, 26020, Sumer Mah. Kar Sokak 10/3, Eskisehir, Turquía
Bibliografía del artículo
1. Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol 31(5):360-367, Oct 2006.
2. Cingi C, Ozlugedik S. Effects of montelukast on quality of life in patients with persistent allergic rhinitis. Otolaryngol Head Neck Surg 142(5):654-658, May 2010.
3. Pinar E, Eryigit O, Oncel S, Calli C, Yilmaz O, Yuksel H. Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis. Auris Nasus Larynx 35(1):61-66, Mar 2008. Epub 7 Sep 2007.
4. Scadding GK. Recent advances in the treatment of rhinitis and rhinosinusitis. Int J Pediatr Otorhinolaryngol 67(Suppl 1):S201-S204, Dec 2003.
5. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Review. Am J Med 116(5):338-344, 1 Mar 2004.
6. van Hoecke H, Vandenbulcke L, van Cauwenberge P. Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update. Review. Drugs 67(18):2717-2726, 2007.
7. Yazici ZM, Sayin I, Bozkurt E, Kayhan FT. Effect of montelukast on quality of life in subjects with nasal polyposis accompanying bronchial asthma. Kulak Burun Bogaz Ihtis Derg 21(4):210-214, Jul-Aug 2011. doi: 10.5606/kbbihtisas.2011.028.
8. Haberal I, Corey JP. The role of leukotrienes in nasal allergy. Review. Otolaryngol Head Neck Surg 129(3):274-279, Sep 2003.
9. Jung TT, Juhn SK, Hwang D, et al. Prostaglandins, leukotrienes, and other arachidonic acid metabolites in nasal polyps and nasal mucosa. Laryngoscope 97:184-189, 1987.
10. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS, van den Oord EJ, Anderson WH. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 17(3):189-196, Mar 2007.
11. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19(2):129-138, Feb 2009.
12. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, Dorinsky PM, Nelson HS. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 128(4):1910-1920, Oct 2005.
13. Weinstein SF, Philip G, Hampel FC Jr, Malice MP, Swern AS, Dass SB, Reiss TF. Onset of efficacy of montelukast in seasonal allergic rhinitis. Allergy Asthma Proc 26(1):41-46, Jan-Feb 2005.
14. Chervinsky P, Philip G, Malice MP, Bardelas J, Nayak A, Marchal JL, van Adelsberg J, Bousquet J, Tozzi CA, Reiss TF. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 92(3):367-373, Mar 2004.
15. Philip G, Williams-Herman D, Patel P, Weinstein SF, Alon A, Gilles L, Tozzi CA, Dass SB, Reiss TF. Efficacy of montelukast for treating perennial allergic rhinitis.Allergy Asthma Proc 28(3):296-304, May-Jun 2007.
16. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, Malice MP, Reiss TF; Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 32(7):1020-1028, Jul 2002.
17. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF; Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 88(6):592-600, Jun 2002.
18. Ciebiada M, Gorska-Ciebiada M, Barylski M, Kmiecik T, Gorski P. Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Am J Rhinol Allergy 25(1):e1-e6, Jan-Feb 2011.
19. Lu S, Malice MP, Dass SB, Reiss TF. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. J Asthma 46(9):878-883, Nov 2009.
20. Saengpanich S, deTineo M, Naclerio RM, Baroody FM. Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Arch Otolaryngol Head Neck Surg 129(5):557-562, May 2003.
21. Chen ST, Lu KH, Sun HL, Chang WT, Lue KH, Chou MC. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol 17(1):49-54, Feb 2006.
22. Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C, Ditta V, Martinelli N, Candore G, Mansueto P, Rini GB, Corrocher R, Caruso C. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 34(2):259-267, Feb 2004.
23. Hill SL 3rd, Krouse JH. The effects of montelukast on intradermal wheal and flare. Otolaryngol Head Neck Surg 129(3):199-203, Sep 2003.
24. Cuhadaroglu C, Erelel M, Kiyan E, Ece T, Erkan F. Role of Zafirlukast on skin prick test. Allergol Immunopathol (Madr) 29(2):66-68, Mar-Apr 2001.
25. Simons FE, Johnston L, Gu X, Simons KJ. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. Ann Allergy Asthma Immunol 86(1):44-50, Jan 2001.
26. Skillman KL, Stumpf JL. Montelukast-induced anxiety in two pediatric patients. Pharmacotherapy 31(5):524, May 2011.
27. Schumock GT, Lee TA, Joo MJ, Valuck RJ, Stayner LT, Gibbons RD. Association between leukotriene-modifying agents and suicide: what is the evidence? Review.
Drug Saf 34(7):533-44, 1 Jul 2011. doi: 10.2165/11587260-000000000-00000.
28. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Review. Lancet 378(9809):2112-2122, 17 Dec 2011. Epub 23 Jul 2011.
29. Nelsen LM, Shields KE, Cunningham ML, Stoler JM, Bamshad MJ, Eng PM, Smugar SS, Gould AL, Philip G. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. J Allergy Clin Immunol 129(1):251-254; e1-e6, Jan 2012. Epub 13 Oct 2011.
30. Singulair (montelukast sodium) Prescribing Information. Whitehouse Station (NJ): Merck & Co, Inc; 2010.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008